Cyclerion Therapeutics Inc
CYCN1.380USD
-0.050-3.50%
收盤 12/24, 13:00（美東）報價延遲15分鐘
5.10M總市值
虧損本益比TTM
關於 Cyclerion Therapeutics Inc 公司
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Cyclerion Therapeutics Inc簡介
公司代碼CYCN
公司名稱Cyclerion Therapeutics Inc
上市日期Mar 18, 2019
CEOGraul (Regina M)
員工數量1
證券類型Ordinary Share
年結日Mar 18
公司地址301 Binney Street
城市CAMBRIDGE
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02142
電話16176217722
網址https://www.cyclerion.com/
公司代碼CYCN
上市日期Mar 18, 2019
CEOGraul (Regina M)
Cyclerion Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Hecht (Peter M)
14.25%
J. Wood Capital Advisors LLC
4.63%
American Endowment Foundation
3.39%
Invus Public Equities Advisors, LLC
2.96%
Graul (Regina Margaret)
1.42%
其他
73.35%
持股股東
持股股東
佔比
Hecht (Peter M)
14.25%
J. Wood Capital Advisors LLC
4.63%
American Endowment Foundation
3.39%
Invus Public Equities Advisors, LLC
2.96%
Graul (Regina Margaret)
1.42%
其他
73.35%
股東類型
持股股東
佔比
Individual Investor
18.74%
Corporation
8.02%
Investment Advisor
5.70%
Investment Advisor/Hedge Fund
0.95%
Hedge Fund
0.40%
Research Firm
0.02%
其他
66.16%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
33
277.64K
23.79%
--
2025Q3
36
277.64K
28.05%
-103.98K
2025Q2
36
381.62K
29.96%
-10.58K
2025Q1
53
392.20K
30.91%
-599.93K
2024Q4
57
398.50K
41.58%
-660.57K
2024Q3
62
1.11M
44.54%
-7.58K
2024Q2
66
1.10M
44.98%
-18.58K
2024Q1
76
1.12M
48.61%
-196.27K
2023Q4
83
1.12M
54.12%
-3.34K
2023Q3
98
1.12M
59.61%
-44.82K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Hecht (Peter M)
559.20K
16.76%
--
--
Apr 21, 2025
J. Wood Capital Advisors LLC
181.82K
5.45%
+181.82K
--
Apr 21, 2025
American Endowment Foundation
133.03K
3.99%
+133.03K
--
Dec 31, 2024
Invus Public Equities Advisors, LLC
116.16K
3.48%
--
--
Jun 30, 2025
Graul (Regina Margaret)
55.78K
1.67%
-44.52K
-44.39%
Apr 21, 2025
De Souza (Errol B)
50.00K
1.5%
--
--
Apr 21, 2025
Geode Capital Management, L.L.C.
32.73K
0.98%
+1.13K
+3.58%
Jun 30, 2025
Higgins (Michael J)
30.74K
0.92%
+1.65K
+5.67%
Apr 21, 2025
The Vanguard Group, Inc.
23.49K
0.7%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
公告日期
類型
比率
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
常見問題
Cyclerion Therapeutics Inc的前五大股東是誰？
Cyclerion Therapeutics Inc的前五大股東如下：
Hecht (Peter M)持有股份：559.20K佔總股份比例：16.76%。
J. Wood Capital Advisors LLC持有股份：181.82K佔總股份比例：5.45%。
American Endowment Foundation持有股份：133.03K佔總股份比例：3.99%。
Invus Public Equities Advisors, LLC持有股份：116.16K佔總股份比例：3.48%。
Graul (Regina Margaret)持有股份：55.78K佔總股份比例：1.67%。
Hecht (Peter M)持有股份：559.20K佔總股份比例：16.76%。
J. Wood Capital Advisors LLC持有股份：181.82K佔總股份比例：5.45%。
American Endowment Foundation持有股份：133.03K佔總股份比例：3.99%。
Invus Public Equities Advisors, LLC持有股份：116.16K佔總股份比例：3.48%。
Graul (Regina Margaret)持有股份：55.78K佔總股份比例：1.67%。
Cyclerion Therapeutics Inc的前三大股東類型是什麼？
Cyclerion Therapeutics Inc 的前三大股東類型分別是：
Hecht (Peter M)
J. Wood Capital Advisors LLC
American Endowment Foundation
Hecht (Peter M)
J. Wood Capital Advisors LLC
American Endowment Foundation
有多少機構持有Cyclerion Therapeutics Inc(CYCN)的股份？
截至2025Q4，共有33家機構持有Cyclerion Therapeutics Inc的股份，合計持有的股份價值約為277.64K，占公司總股份的23.79% 。與2025Q3相比，機構持股有所增加，增幅為-4.26%。
哪個業務部門對Cyclerion Therapeutics Inc的收入貢獻最大？
在--，--業務部門對Cyclerion Therapeutics Inc的收入貢獻最大，創收--，占總收入的--% 。
